- Associated Press - Friday, January 7, 2011

GENEVA (AP) - Swiss pharmaceutical company Novartis AG says it has received approval from European regulators to market a new drug to treat vision problems resulting from diabetes.

Novartis says Lucentis is the first drug to be licensed for treatment of vision loss due to diabetic macular edema.

The Basel-based company says half of patients saw their vision significantly improve during two clinical trials.

Lucentis is already licensed for other conditions including wet acute macular degeneration.

Novartis says diabetic macular edema is a leading cause of blindness in most developed countries in the working-age population.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide